Cyclic neutropenia in animals

To the editor: Pacheco et al. [1] recently published in these pages an allometric scaling analysis of cyclic neutropenia (CN) in mammals, using as reference points the hereditary disorders in humans and in gray collie dogs [2]. They make a central assumption ‘‘that the biological defect in CN is the same in dogs and in humans.’’ However, virtually all human cases derive from mutations in the neutrophil elastase (ELA2) gene [3], whereas the disorder in dogs represents a similar hematological phenotype, in association with partial albinism, because of the defects in the adaptor protein complex 3 (AP3) b-subunit, directing trans-Golgi export of transmembrane cargo proteins to lysosomes [4]. Thus, the canine disorder better models Hermansky–Pudlak syndrome Type 2, [5] than human CN. Although the genetic defects in man and dog may share common downstream mechanisms involving elastase trafficking or elicitation of the unfolded protein response, the resultant kinetics of apoptosis induction and recovery in myeloid precursors may not be the same, and thus the assumption may not be correct.

[1]  F. Kamali,et al.  Vitamin K deficiency amplifies anticoagulation response to ximelagatran: possible implications for direct thrombin inhibitors and their clinical safety , 2009, Annals of Hematology.

[2]  Arne Traulsen,et al.  Cyclic neutropenia in mammals , 2008, American journal of hematology.

[3]  S. Austin,et al.  The JAK2V617F mutation and thrombosis , 2008, British journal of haematology.

[4]  A. Giorgetti,et al.  Loss of the JAK2 intramolecular auto‐inhibition mechanism is predicted by structural modelling of a novel exon 12 insertion mutation in a case of idiopathic erythrocytosis , 2008, British journal of haematology.

[5]  W. Vainchenker,et al.  Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F‐negative polycythaemia vera patients , 2008, British journal of haematology.

[6]  F. Rodeghiero,et al.  A new TMHA‐DHPLC assay for the rapid mutation screening of JAK2 exon 14 in myeloproliferative disorders , 2008, American journal of hematology/oncology.

[7]  R. Kralovics,et al.  Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. , 2008, Blood.

[8]  J. Gécz,et al.  Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients , 2008, Leukemia.

[9]  M. Cazzola,et al.  Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. , 2008, Blood.

[10]  A. Green,et al.  The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels , 2007, Haematologica.

[11]  B. Bellosillo,et al.  JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis , 2007, Haematologica.

[12]  J. Spivak,et al.  Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. , 2007, Experimental hematology.

[13]  G. Tiscia,et al.  A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. , 2007, Blood.

[14]  C. Bloomfield,et al.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. , 2007, Blood.

[15]  T. Barbui,et al.  Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. , 2007, Blood.

[16]  F. Kamali,et al.  Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. , 2007, Blood.

[17]  Stephen J Salipante,et al.  Neutrophil elastase in cyclic and severe congenital neutropenia. , 2007, Blood.

[18]  M. Stratton,et al.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.

[19]  A. Schäffer,et al.  Identification of a homozygous deletion in the AP3B1 gene causing Hermansky-Pudlak syndrome, type 2. , 2006, Blood.

[20]  T. Barbui,et al.  Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. , 2005 .

[21]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[22]  L. Rohde,et al.  Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. , 2004, The American journal of medicine.

[23]  M. Horwitz,et al.  Congenital and acquired neutropenia. , 2004, Hematology. American Society of Hematology. Education Program.

[24]  J. Bussel,et al.  Intravenous anti‐D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy , 2003, British journal of haematology.

[25]  G. Acland,et al.  Mutations associated with neutropenia in dogs and humans disrupt intracellular transport of neutrophil elastase , 2003, Nature Genetics.

[26]  M. Shearer,et al.  Intake and sources of phylloquinone (vitamin K1): variation with socio-demographic and lifestyle factors in a national sample of British elderly people. , 2002, The British journal of nutrition.

[27]  T. Pearson Evaluation of diagnostic criteria in polycythemia vera. , 2001, Seminars in hematology.

[28]  C Bos,et al.  Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. , 2000, Blood.

[29]  T. Barbui,et al.  Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long‐term follow‐up of a randomized clinical trial , 2000, British journal of haematology.

[30]  S. Booth,et al.  Vitamin K: a practical guide to the dietary management of patients on warfarin. , 2009, Nutrition reviews.

[31]  J. George,et al.  Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. , 1996, Blood.

[32]  D. Dale,et al.  Cyclic neutropenia: a clinical review. , 1988, Blood reviews.